Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulbutiamine vs Imipramine for Nocturnal Enuresis
NCT06497647Recruiting
- Sponsor
- Sohag University
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sulbutiamine in nocturnal enuresis (NE) (3 arms), sponsored by Sohag University. Primary endpoint: Reduction in the number of wet nights at 3 months. Started Mar 2024; status: recruiting.
02
Drugs
sulbutiamine
03
Conditions
nocturnal enuresis (NE)
Beyond the preview
Go deeper on NCT06497647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497647.